Responses
Late-breaking abstracts
Clinical trials completed
793 TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent/metastatic (R/M) human papilloma virus (HPV)-16+ cancers: clinical efficacy and immunogenicity
Compose a Response to This Article
Other responses
No responses have been published for this article.
